Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30486269 | 1.00 | MAP4K4 (0.51) | MAP4K4HRH3AURKAAURKBSIGMAR1 | |
| SCHEMBL29984833 | 0.94 | HRH3 (0.55) | HRH3SIGMAR1 | |
| SCHEMBL4416516 | 0.94 | MAP4K4 (0.57) | MAP4K4HRH3SIGMAR1KDM4E | |
| SCHEMBL31298956 | 0.94 | MAP4K4 (0.57) | MAP4K4HRH3SIGMAR1KDM4E | |
| SCHEMBL4424443 | 0.92 | MAP4K4 (0.56) | MAP4K4HRH3SIGMAR1MAOB | |
| SCHEMBL4425324 | 0.90 | HRH3 (0.54) | MAP4K4HRH3AURKAAURKBSIGMAR1 | |
| SCHEMBL30783040 | 0.89 | SRC (0.55) | HRH3AURKAAURKBSIGMAR1 | |
| SCHEMBL4429202 | 0.89 | SRC (0.55) | HRH3AURKAAURKBSIGMAR1 | |
| SCHEMBL4420110 | 0.87 | HPGD (0.44) | MAP4K4HRH3AURKAAURKBSIGMAR1 | |
| SCHEMBL4431344 | 0.84 | SIGMAR1 (0.50) | MAP4K4HRH3AURKAAURKBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | MAP4K4 3090/4885HRH3 587/4885AURKA 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.